Que retenir des recommandations de la Société Européenne de Cardiologie et de la Société Européenne d’Athérosclérose (2019) sur le traitement des dyslipidémies pour la prévention des maladies cardiovasculaires ?

Descamps, Olivier;De Sutter, Johan;Mertens, Ann;Wallemacq, Caroline;Persu, Alexandre;et.al.
(2020) Louvain médical — Vol. 139, n° 7, p. 396-404 (2020)

Files

2020_LouMed_13907.pdf
  • Open Access
  • Adobe PDF
  • 3.03 MB
Download
2020_Descamps_LouMed_396-404.pdf
  • Restricted Access
  • Adobe PDF
  • 2.7 MB
Request a copy

Details

Authors
  • Descamps, OlivierUCLouvain
    Author
  • De Sutter, Johan
    Author
  • Mertens, Ann
    Author
  • Wallemacq, Caroline
    Author
  • Balligand, Jean-LucUCLouvain
    Collaborator
  • Beauloye, ChristopheUCLouvain
    Collaborator
  • Chenu, PatrickUCLouvain
    Collaborator
  • Demeure, FabianUCLouvain
    Collaborator
  • Hermans, MichelUCLouvain
    Collaborator
  • Persu, Alexandreorcid-logoUCLouvain
    Collaborator
Show more
Abstract
(en) [What should be taken into account from the 2019 recommendations of the European Atherosclerosis Society and European Society of Cardiology concerning dyslipidemia management for preventing atherosclerotic cardiovascular disease?] Several members of the Belgian Societies of Atherosclerosis and Cardiology have revisited in the form of 10 questions the main points of the new recommendations of the European Atherosclerosis Society (EAS) and European Society of Cardiology (ESC) concerning dyslipidemia management for preventing atherosclerotic cardiovascular disease (AVD). These new guidelines are underpinned by a number of key concepts, including the certainty that LDL cholesterol is the major cause underlying the development of atherosclerosis, that reducing LDL cholesterol helps diminish cardiovascular risk, that this cardiovascular benefit is the same regardless of how this reduction is met (nutrition, statin, ezetimibe, or PCSK9 inhibitor), and that there is neither a lower limit to this effect nor any danger at all of extremely low LDL cholesterol levels.To effectively put this knowledge into practice, a step-by-step approach is recommended; thereby enabling us to weight the intensity of the preventive approach based on individuals’ overall MCVA risk and their baseline (untreated) LDL-C levels.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Descamps, O., De Sutter, J., Mertens, A., Wallemacq, C., Langlois, M., Verhaegen, A., Rietzschel, E., & De Backer, G. (2020). Que retenir des recommandations de la Société Européenne de Cardiologie et de la Société Européenne d’Athérosclérose (2019) sur le traitement des dyslipidémies pour la prévention des maladies cardiovasculaires ? Louvain médical, 139(7), 396-404. https://hdl.handle.net/2078.5/168850 (Original work published 2020)